Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Share:
Related CERN
Benzinga's Top Upgrades
Barron's Picks And Pans: Interpublic, Zimmer Biomet And More
Healthcare ratings roundup - upgrades/downgrades (Seeking Alpha)
Related ABCO
Credit Suisse All Aboard The Advisory Board
Benzinga's Top Upgrades

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Jun 2016SunTrust Robinson HumphreyUpgradesNeutralBuy
Feb 2016Goldman SachsDowngradesBuyNeutral
Feb 2016Evercore ISI GroupDowngradesBuyHold

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

View Comments and Join the Discussion!